Important know-how and the highest quality standards characterize the experience and services offered by NerPharMa: from production of the active principle to formulation, from packaging to the management of the clinical supply chain, to Regulatory approvals in different countries, with a strategic competence in the development and optimization of the entire process.

The company, part of NMS Group, operates in fact as a Contract Development and Manufacturing Organization (CDMO) and is characterized by a strong specialization in oncology, which guarantees the highest standards of quality and control.

NerPharMa owns a wide and cutting edge organizational structure able to manage and manipulate highly active compounds, and to ensure the full development and production of active principles and finished products intended for the world market as well as the research and development of new compounds.

NerPharMa DP is dealing with the development and manufacturing of compounds, injectables (solutions and lyophilized) and solid oral (tablets and capsules) for various therapeutic areas, with handling of cytotoxic and cytostatic finished products (not just oncological) and activities of formulation, packaging and distribution and NerPharMa DS is dealing with the development and production of active principles only oncological (and also cytotoxic/cytostatic), moving from laboratory scale to commercial products.

In addition, the plant is managed in accordance with Current Good Manufacturing Practices (cGMP) and is authorized by the Italian Drug Agency (AIFA) to the production of both pharmaceutical active principles and finished products. Considering the importance of the structure on the reference international market, the production facilities have also received over the years the approval of the Food and Drug Administration (FDA) as well as the certification PMDA for the production of commercial products.

Further details at Nerpharma website and follow Nerpharma on LinkedIn.